Farouk M, Vigna S R, McVey D C, Meyers W C
Department of Surgery, Duke University Medical Center, Durham, North Carolina.
Gastroenterology. 1992 Mar;102(3):963-8. doi: 10.1016/0016-5085(92)90183-y.
The goal of the present studies was to identify and characterize the site of secretin action in the liver. Sections of normal and bile duct-ligated rat livers were used for in vitro 125I-secretin receptor autoradiography. Saturable binding was observed in both normal and bile duct-ligated livers but was much greater in the bile duct-ligated preparations. Binding was limited to biliary epithelium and the increased secretin binding observed in the ligated livers correlated with the increase in ductular tissue. Saturable binding was inhibited in a dose-dependent fashion by increasing concentrations of nonradioactive secretin. Analysis of saturation binding showed that 125I-secretin binding was best fit by a one-site receptor model with a Kd of 5.3 +/- 1.1 nmol/L. Glucagon, vasoactive intestinal polypeptide, gastric inhibitory polypeptide, growth hormone-releasing hormone, and cholecystokinin did not inhibit saturable 125I-secretin binding at concentrations of 1 pmol/L to 1 mumol/L. The authors conclude that high-affinity, specific secretin binding sites are present in rat intrahepatic biliary epithelium. When bile ducts are stimulated to proliferate by bile duct ligation, secretin binding is also increased.
本研究的目的是确定并描述促胰液素在肝脏中的作用位点。使用正常大鼠和胆管结扎大鼠肝脏的切片进行体外125I-促胰液素受体放射自显影。在正常肝脏和胆管结扎肝脏中均观察到可饱和结合,但在胆管结扎制剂中结合量要大得多。结合仅限于胆管上皮,在结扎肝脏中观察到的促胰液素结合增加与小胆管组织的增加相关。随着非放射性促胰液素浓度的增加,可饱和结合以剂量依赖性方式受到抑制。饱和结合分析表明,125I-促胰液素结合最适合用单点受体模型拟合,其解离常数(Kd)为5.3±1.1 nmol/L。胰高血糖素、血管活性肠多肽、胃抑制多肽、生长激素释放激素和胆囊收缩素在1 pmol/L至1 μmol/L的浓度下均不抑制可饱和的125I-促胰液素结合。作者得出结论,大鼠肝内胆管上皮存在高亲和力、特异性的促胰液素结合位点。当通过胆管结扎刺激胆管增殖时,促胰液素结合也会增加。